Making Drugs to Combat Major Human Diseases
EDMONTON, Sept. 26, 2011 /CNW/ - Compass (COBI:OB) is pleased to announce new research findings that it believes will alter
the course of HCV vaccine development and other vaccines in general. Vaccine products continue to be the success story for pharmaceutical companies,
with the world market for preventative vaccines in 2010 being $ 28
billion as compared to $26 billion in 2009, $24 billion in 2008 and
$18.5 billion in 2007.
"The Hepatitis C Vaccine market potential for Compass is approximately
US$2 billion, but with the development of a second anti HCV type
product based on new scientific findings that augments to make a HCV
vaccine even more potent, then this means that sales could jump to much
higher levels. We would be the market leaders in this area "commented
Garth Likes CEO.
New studies have contributed to the understanding of a previously
unknown mechanism of antibody-mediated Hepatitis C Virus (HCV)
neutralization and interference. It was found that while the human
immune system produces neutralizing antibodies against HCV, a second
interfering antibody is also created which stops the neutralizing
antibodies from being totally effective or interacting and killing the
The findings suggest that, if this interfering mechanism operates in
humans during HCV infection, and that neutralizing antibodies can be
impeded by a second interfering antibody binding; then this may account
for the persistence of HCV infection even in the presence of an
abundance of neutralizing antibodies.
Dr. Joseph Sinkule, the President and COO of Compass stated "we are now
working on an approach using peptide-blocking or single chain
antibodies against HCV epitope-II to remove the restraints imposed by
interfering antibodies to epitope-II. We believe this epitope blocking
approach, combined with VLP immunization and the generation of
neutralizing antibodies to epitope-I could result in cross-genotype
neutralization - the holy grail of HCV vaccine development."
This new combination of vaccine plus use of developing anti-interference
molecules will allow Compass to develop drugs which could provide a
practical and targeted approach to the development of a more potent and
broadly reactive hepatitis C therapeutic vaccine.
Further Technical Background:
The Company previously announced an exclusive worldwide license from the
NIH regarding technology to make artificial virus-like particles (VLPs)
made from expression of virus proteins or capsids, E1 and E2, which are
structural proteins of the HCV virus. Thus Compass is making a VLP
vaccine that will allow the body to make antibodies against the
structural Hepatitis C proteins E1 and E2.
The Company's HCV VLPS have been used by numerous researchers as a model
system to discover how the HCV virus infects the human liver cells and
identifying potential mechanisms that might be used to prevent
infection of the human cell by the virus. In the course of
experimentation to identify antibodies that might neutralize or block
HCV virus entry, investigators have identified neutralizing epitopes
(sites) on the E2 protein that are directly implicated by several
laboratories in virus neutralization and inhibition of infection.
The inventor of Compass' technology developed an HCV-LP-based model
system for a systematic functional analysis of antiviral antibodies
from patients with acute or chronic hepatitis C infection. They
demonstrated that cellular HCV binding was specifically inhibited by
antiviral antibodies isolated from serum of patients with acute or
chronic hepatitis C infection in a dose-dependent manner. In other
laboratories at the NIH, researchers used purified human immune
globulins from HCV-positive patients, and similarly identified two
antibody epitopes in the E2 protein of the HCV virus. It was shown that
epitope-I was implicated in HCV neutralization whereas the binding of a
non-neutralizing antibody to epitope-II disrupted virus neutralization
mediated by antibody binding at epitope-I.
ABOUT COMPASS BIOTECHNOLOGIES INC.
www.compassbio.net -Please visit our website for updated news and reports
Compass Biotechnologies, Inc. (COBI:OB) is a publically-traded specialty
drug company with a mission to development and commercialization of
drugs, peptides, and proteins to combat major human diseases. Compass
Biotechnologies, Inc. (Compass) is working on two therapeutic platforms
- recombinant biosimilars and biobetters, and combating viral hepatitis
infection by developing drugs to treat existing disease and vaccines to
prevent disease. Under an exclusive worldwide license from the National
Institutes of Health (NIH), the Company has opportunities to develop
HCV VLP vaccine products using patented technology to manufacture
virus-like particles (VLPs).
Compass has previously announced an agreement with PanGen Biotech of
Seoul, South Korea to provide Compass with a wide array of recombinant
protein biosimilars manufactured in "CHO" cells, and a relationship
with Arecor Ltd. of Cambridge, England to develop a biobetter,
heat-stable formulation of the commercial hepatitis B vaccine. The
Company is also pursuing a near-term revenue generation strategy by
commercializing Compass' own brand of generic ribavirin (400 mg and 600
mg tablets) through collaboration with Aurobindo Pharmaceuticals and
pegylated alpha interferon, the mainstays of anti-viral drug therapy
used to treat hepatitis B and hepatitis C infections. The annual
hepatitis market for the two drugs is estimated at over US$4 Billion.
Forward Looking Statements
This news release contains "forward-looking statements", as that term is
defined in Section 27A of the United States Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Statements in this
current report which are not purely historical are forward-looking
statements and include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainty of financial estimates and projections, the competitive and
regulatory environments, stock market conditions, unforeseen technical
difficulties and our ongoing ability to operate a business and obtain
financing. These forward-looking statements are made as of the date of
this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual results
could differ from those projected in the forward-looking statements.
Although we believe that our beliefs, plans, expectations and
intentions contained in this current report are reasonable, there can
be no assurance that such beliefs, plans, expectations or intentions
will prove to be accurate. Investors should consult all of the
information set forth herein and should also refer to the risk factors
disclosure outlined in our quarterly reports on Form 10-Q and our other
periodic reports filed from time-to-time with the Securities and
Exchange Commission pursuant to the Securities Exchange Act.
SOURCE Compass Biotechnologies Inc.
For further information:
For further information and inquiries:
Interactive Business Alliance LLC
Zachary R. Logan